Credit Suisse Group Analysts Give Bayer (FRA:BAYN) a €70.00 Price Target

Credit Suisse Group set a €70.00 ($81.40) price target on Bayer (FRA:BAYN) in a report released on Wednesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

A number of other equities analysts also recently commented on BAYN. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the stock a buy rating in a report on Tuesday. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the stock a buy rating in a report on Tuesday. JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer and gave the stock a neutral rating in a report on Tuesday. Sanford C. Bernstein set a €90.00 ($104.65) price objective on Bayer and gave the stock a buy rating in a report on Tuesday. Finally, HSBC set a €63.00 ($73.26) price objective on Bayer and gave the stock a neutral rating in a report on Monday, July 1st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of €80.61 ($93.73).

Bayer stock opened at €58.00 ($67.44) on Wednesday. The stock has a 50-day moving average price of €58.37. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: Find a Trading Strategy That Works

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.